MGD-Associated Dry Eye Disease – How Emerging Options May Shift the Treatment Paradigm

Release Date: December 21, 2022

Expiration Date: December 21, 2023

Activity Overview

Meibomian gland dysfunction (MGD) is a complex, multifactorial disorder that can lead to altered tear film composition and ocular surface disease. In fact, MGD is one of the most common causes of dry eye disease (DED). Although multiple treatment options are available, therapies that target the underlying pathophysiology of the disease are lacking. Emerging agents with novel mechanisms for treating MGD may ultimately provide new treatment alternatives.

This Community Practice Connections™ program provides an in-depth review of some of the key highlights from a live symposium held during the American Academy of Optometry Annual Meeting 2022 in October. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects of managing patients with MGD-associated DED, putting recent clinical trial data into clinical context. The program is designed for clinicians who did not attend the live meeting and to help reinforce learnings for those who did.

Target Audience

The target audience for this activity is optometrists and other health care professionals who are involved in the management of patients with MGD-associated DED.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Distinguish burden of disease associated with MGD-associated DED
• Analyze key trial data surrounding therapies used for the treatment of MGD-associated DED
• Recognize the mechanisms of action of emerging agents for the treatment of MGD-associated DED
• Evaluate safety, efficacy, and key clinical trial data for emerging agents being studied for the potential treatment of MGD-associated DED

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.